A New Test for Heparin-Induced Thrombocytopenia (HIT)
An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia
This project is developing a more accurate and faster blood test to identify patients who have a serious reaction to heparin, called Heparin-induced Thrombocytopenia (HIT).
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Retham Technologies, INC. NIH-funded |
| Lab location | 1 site (Wauwatosa, UNITED STATES) |
| Project ID | NIH-11043284 on NIH RePORTER |
What this research studies
Heparin-induced Thrombocytopenia (HIT) is a severe reaction to heparin that can be life-threatening. Current tests for HIT are often either not very accurate, leading to unnecessary treatments, or they take too long to provide results. This new test aims to quickly and precisely identify the specific antibodies in your blood that cause HIT. By doing so, it could help doctors make faster, more informed decisions about your care, avoiding delays or treatments you don't need.
Who could benefit from this research
Good fit: This research is relevant for patients who are treated with heparin and are suspected of having Heparin-induced Thrombocytopenia (HIT).
Not a fit: Patients who are not receiving heparin or do not have symptoms of HIT would not directly benefit from this specific diagnostic test.
Why it matters
Potential benefit: If successful, this new diagnostic test could lead to earlier and more accurate diagnosis of HIT, preventing serious complications and improving patient outcomes.
How similar studies have performed: While current HIT tests have limitations, this project builds on findings that specific platelet treatments can improve the sensitivity and specificity of antibody detection.
Where this research is happening
Wauwatosa, UNITED STATES
- Retham Technologies, INC. — Wauwatosa, United States (Active)
Researchers
- Principal investigator: Jones, Curtis — Retham Technologies, INC.
- Study coordinator: Jones, Curtis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.